PMID: 6993570May 1, 1980

Human graft versus host disease

The Journal of Investigative Dermatology
R ParkmanF Rosen

Abstract

Human graft versus host disease is composed of 2 distinct clinical entities, acute graft versus host disease and chronic graft versus host disease, which have different pathogenesis. Acute graft versus host disease is produced by the attack of donor immunocompetent T or null lymphocytes against recipient histocompatibility antigens. The null lymphocytes may attack antigens shared by the donor and recipient and are autocytotoxic lymphocytes which can produce acute graft versus host disease in recipients of identical twin transplants. The cessation of acute graft versus host disease occurs when suppressor lymphocytes appear in the recipient's peripheral circulation. Chronic graft versus host disease is produced by immunocompetent lymphocytes that differentiate in the recipient. Its control is unknown. Some patients with chronic graft versus host disease have in vivo activated suppressor lymphocytes which produce a secondary immunoincompetence and an increased susceptibility to bacterial sepsis and death.

References

Apr 1, 1976·Transplantation·M M BortinE C Saltzstein
Dec 1, 1977·Annals of Internal Medicine·A A GratwohlA B Deisseroth
Apr 1, 1979·The American Journal of Medicine·P R Graze, R P Gale
Apr 24, 1975·The New England Journal of Medicine·E D ThomasC D Buckner

Citations

Dec 12, 2012·Journal of Biomedicine & Biotechnology·Fernando de Sá SilvaCarlos Magno da Costa Maranduba
Feb 23, 2013·Clinical & Developmental Immunology·Ravi StarzlXin Xiao Zheng
May 1, 1985·Journal of the American Academy of Dermatology·M G Connelly, R K Winkelmann
Sep 1, 1983·Journal of the American Academy of Dermatology·B TolbertD Brubaker
Nov 1, 1991·The British Journal of Dermatology·R J van Dooren-GreebeR J Koopman
Apr 1, 1989·International Journal of Dermatology·W R Heymann
Apr 1, 1996·The British Journal of Dermatology·A NaglerS N Klaus
Jan 26, 2006·Experimental Dermatology·W WegerC Pertl
Dec 1, 1991·Pediatric Dermatology·C Postigo LlorenteL Iglesias Díez
Jan 1, 1986·International Journal of Cell Cloning·K M Sullivan
Jan 1, 1985·Archives of Dermatological Research·J C RoujeauR Touraine
Jan 1, 1983·Critical Reviews in Clinical Laboratory Sciences·P L Weiden
Jan 1, 1984·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·D C SnoverJ H Kersey
Jun 1, 1986·The Journal of Dermatology·I KatayamaK Nishioka
Oct 1, 1983·Journal of Cutaneous Pathology·A L ClaudyS Boucheron
May 1, 1992·British Journal of Haematology·E R KaminskiJ R Batchelor
Apr 15, 1982·The New England Journal of Medicine
Sep 1, 1996·International Journal of Dermatology·A WoscoffA Robinson
Sep 1, 1982·International Journal of Dermatology·T L Ray
Jan 1, 1988·Immunopharmacology and Immunotoxicology·S R SmithS Umland

Related Concepts

Antibody Formation
Graft Vs Host Reaction
Lymphoid Cells
Transplantation, Homologous
Bone Marrow Cell Transplantation

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.